Equities

Medipharm Labs Corp

Medipharm Labs Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)0.07
  • Today's Change0.00 / 0.00%
  • Shares traded16.88k
  • 1 Year change+7.69%
  • Beta0.9633
Data delayed at least 15 minutes, as of Nov 22 2024 14:37 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.

  • Revenue in CAD (TTM)39.05m
  • Net income in CAD-11.93m
  • Incorporated2017
  • Employees166.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kane Biotech Inc757.12k-5.48m14.50m--------19.16-0.0420.03740.0059-0.00550.15680.37513.23---113.43-77.89----60.5443.27-723.31-241.850.5679-4.731.43---94.42-20.26-17.29---19.41--
Pharmacielo Ltd1.62m-14.15m15.82m268.00------9.76-0.0849-0.08490.0097-0.0320.06991.3824.15---61.03---165.82---86.39---873.57--0.039-2.481.37---70.96---12.27------
Cytophage Technologies Ltd0.00-7.80m17.53m----3.32-----0.3779-0.37790.000.0978----------------------------0.2374-------25.88------
Devonian Health Group Inc9.75m-3.17m18.53m6.00--1.39--1.90-0.0216-0.02160.06650.090.442333.072.321,625,238.00-14.37-21.02-23.15-23.9630.9529.96-32.50-131.971.06-9.410.1406--1.74-5.83-33.39------
Medicus Pharma Ltd0.00-16.39m27.66m----3.07-----3.56-3.560.000.83090.00-------267.24-652.37-371.17-------------20.260.0549-------300.86------
Charlotte's Web Holdings Inc73.82m-48.98m28.35m164.00--0.6721--0.384-0.3138-0.31380.47280.26780.37281.3225.80450,149.20-24.73-25.71-28.95-29.0347.2548.98-66.35-63.111.85--0.599---14.82-1.9059.88---7.88--
Decibel Cannabis Company Inc94.96m-1.51m28.77m----0.62510.560.3029-0.0037-0.01190.22920.1040.69441.455.59---1.10-3.55-1.84-5.1929.2815.77-1.59-7.130.4066-2.960.5147--46.18--60.33---32.45--
Medipharm Labs Corp39.05m-11.93m28.77m166.00--0.6388--0.7369-0.0337-0.03370.1060.10960.63063.155.47235,241.00-19.27-32.88-23.78-39.5620.87-5.88-30.56-67.662.36--0.0143--49.4926.5256.37---49.66--
Data as of Nov 22 2024. Currency figures normalised to Medipharm Labs Corp's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.